Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

JAK2 Translocations in hematological malignancies: Review of the literature.

Ho K, Valdez F, Garcia R, Tirado CA.

J Assoc Genet Technol. 2010;36(3):107-9.

PMID:
20978341
2.

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.

Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP.

Eur J Haematol. 2010 Jun;84(6):518-24. doi: 10.1111/j.1600-0609.2010.01428.x. Epub 2010 Mar 11.

PMID:
20331734
3.

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P.

Blood. 1997 Oct 1;90(7):2535-40.

4.

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease.

Elnaggar MM, Agersborg S, Sahoo T, Girgin A, Ma W, Rakkhit R, Zorrilla I, Leal A.

Mol Cytogenet. 2012 May 1;5(1):23. doi: 10.1186/1755-8166-5-23.

6.

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.

Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P.

Oncogene. 2005 Nov 3;24(48):7248-52.

PMID:
16091753
7.

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC.

Cancer Res. 2005 Apr 1;65(7):2662-7.

8.

Chronic myeloproliferative disorders: a tyrosine kinase tale.

De Keersmaecker K, Cools J.

Leukemia. 2006 Feb;20(2):200-5. Review.

PMID:
16341034
9.

8p11 myeloproliferative syndrome: a review.

Jackson CC, Medeiros LJ, Miranda RN.

Hum Pathol. 2010 Apr;41(4):461-76. doi: 10.1016/j.humpath.2009.11.003. Review.

PMID:
20226962
10.

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Drexler HG, MacLeod RA, Uphoff CC.

Leuk Res. 1999 Mar;23(3):207-15. Review.

PMID:
10071072
11.

PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.

Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A.

Expert Opin Ther Targets. 2011 Jan;15(1):53-62. doi: 10.1517/14728222.2011.538683. Epub 2010 Nov 20. Review.

PMID:
21091042
13.

The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.

Holroyd A, Cross NC, Macdonald DH.

Leuk Res. 2011 Oct;35(10):1279-85. doi: 10.1016/j.leukres.2011.05.037. Epub 2011 Jul 1. Review.

PMID:
21722956
14.

The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia.

De Braekeleer M, Morel F, Le Bris MJ, Herry A, Douet-Guilbert N.

Anticancer Res. 2005 May-Jun;25(3B):1931-44. Review.

15.

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.

Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo ML.

Rev Invest Clin. 2006 Sep-Oct;58(5):458-61.

PMID:
17408106
16.

A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27.

Tirado CA, Shabsovich D, DeNicola M, Rao D, Yang L, Garcia R, Rao N.

Biomark Res. 2013 Nov 25;1(1):31. doi: 10.1186/2050-7771-1-31.

17.

[Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].

Zhu Y, Xu W, Liu Q, Pan J, Qiu H, Wang R, Qiao C, Jiang Y, Zhang S, Fan L, Zhang J, Shen Y, Xue Y, Li J.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Oct;25(5):579-82. Chinese.

PMID:
18841577
18.

JAK2 in myeloproliferative disorders is not just another kinase.

Tefferi A, Gilliland DG.

Cell Cycle. 2005 Aug;4(8):1053-6. Epub 2005 Aug 26.

PMID:
15970705
19.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO).

Br J Haematol. 2012 Jan;156(1):76-88. doi: 10.1111/j.1365-2141.2011.08918.x. Epub 2011 Nov 3.

PMID:
22050763
20.

ALL1 gene alterations in acute leukemia: biological and clinical aspects.

Cimino G, Rapanotti MC, Sprovieri T, Elia L.

Haematologica. 1998 Apr;83(4):350-7. Review.

Supplemental Content

Support Center